DENTSPLY SIRONA (XRAY) Upgraded to Strong-Buy by BidaskClub

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday, BidAskClub reports.

Other analysts also recently issued research reports about the stock. ValuEngine upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Barrington Research upgraded shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $63.00 price target for the company in a report on Monday, May 6th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Monday, May 6th. HC Wainwright restated a “neutral” rating and set a $55.00 price target (up previously from $49.00) on shares of DENTSPLY SIRONA in a report on Monday, May 6th. Finally, UBS Group began coverage on shares of DENTSPLY SIRONA in a report on Thursday, January 17th. They set a “neutral” rating and a $42.00 price target for the company. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $53.65.

Shares of NASDAQ XRAY traded up $0.10 during midday trading on Wednesday, reaching $54.97. 986,067 shares of the stock were exchanged, compared to its average volume of 1,838,655. The company has a market capitalization of $12.84 billion, a P/E ratio of 27.35, a P/E/G ratio of 2.04 and a beta of 1.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.06 and a quick ratio of 1.35. DENTSPLY SIRONA has a twelve month low of $33.93 and a twelve month high of $55.88.



DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.10. The business had revenue of $946.20 million during the quarter, compared to the consensus estimate of $925.13 million. DENTSPLY SIRONA had a negative net margin of 26.48% and a positive return on equity of 8.99%. The business’s revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 EPS. As a group, research analysts expect that DENTSPLY SIRONA will post 2.34 EPS for the current year.

In other DENTSPLY SIRONA news, Director Michael J. Coleman sold 9,160 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $54.90, for a total value of $502,884.00. Following the completion of the transaction, the director now owns 31,383 shares of the company’s stock, valued at approximately $1,722,926.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Markus Boehringer sold 25,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $54.83, for a total transaction of $1,387,199.00. Following the completion of the transaction, the insider now directly owns 28,212 shares of the company’s stock, valued at approximately $1,546,863.96. The disclosure for this sale can be found here. Insiders sold a total of 101,022 shares of company stock valued at $5,535,985 in the last quarter. 0.62% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the business. IFM Investors Pty Ltd boosted its position in DENTSPLY SIRONA by 1.8% in the 4th quarter. IFM Investors Pty Ltd now owns 13,533 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 245 shares during the period. Nomura Asset Management Co. Ltd. boosted its position in DENTSPLY SIRONA by 0.7% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 39,575 shares of the medical instruments supplier’s stock valued at $1,473,000 after buying an additional 268 shares during the period. Advisor Partners LLC boosted its position in DENTSPLY SIRONA by 3.1% in the 1st quarter. Advisor Partners LLC now owns 10,169 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 304 shares during the period. Biltmore Family Office LLC boosted its position in DENTSPLY SIRONA by 5.8% in the 1st quarter. Biltmore Family Office LLC now owns 5,715 shares of the medical instruments supplier’s stock valued at $284,000 after buying an additional 315 shares during the period. Finally, Private Capital Group LLC boosted its position in DENTSPLY SIRONA by 105.3% in the 4th quarter. Private Capital Group LLC now owns 700 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 359 shares during the period. 95.83% of the stock is owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

See Also: What is a back-end load?

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.